Key result
Resuming OACs after ICH in AF appears to reduce mortality and thromboembolism without increasing recurrent hemorrhage.
Why the study?
Current literature shows inconsistencies and a lack of definitive guidelines regarding the safety and efficacy of resuming oral anticoagulants in patients with AF after an intracranial hemorrhage.
Does the resumption of oral anticoagulants reduce thromboembolic events and mortality without increasing recurrent intracranial hemorrhage in adult patients with atrial fibrillation who have survived a prior intracranial hemorrhage?
Systematic Review
Does the resumption of oral anticoagulants reduce thromboembolic events and mortality without increasing recurrent intracranial hemorrhage in adult patients with atrial fibrillation who have survived a prior intracranial hemorrhage?
Resuming oral anticoagulants, particularly DOACs, in atrial fibrillation patients with a history of intracranial hemorrhage appears to reduce mortality and thromboembolic events without significantly increasing recurrent bleeding, highlighting the need for definitive RCTs to guide clinical practice.
May support resuming oral anticoagulants in selected AF patients post-ICH; leaves open need for definitive RCTs.
Atrial fibrillation (AF) is the most prevalent arrhythmia, significantly increasing the risk of stroke and thromboembolism. Oral anticoagulants (OACs), including direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs), have been shown to reduce these risks effectively. However, the administration of OACs carries a notable risk of spontaneous intracranial hemorrhage (ICH), a severe complication associated with high morbidity and mortality. Patients with a history of ICH face a complex decision regarding the resumption of anticoagulation therapy, as the likelihood of recurrence is heightened in this population. Current literature reveals inconsistencies in research findings regarding the safety and efficacy of restarting OACs after ICH. A lack of definitive guidelines addressing this issue leaves clinicians uncertain about optimal management strategies. This systematic review aims to analyze existing observational studies and randomized controlled trials (RCTs) to evaluate the safety and effectiveness of resuming OACs in patients with AF who have experienced ICH. The review underscores the urgent need for high-quality research to inform clinical practices and develop comprehensive guidelines for managing anticoagulation therapy in this vulnerable group.
No takes yet. Share an insight, caveat, or question.
Azad Mojahedi (2025) conducted a systematic review in Atrial fibrillation with a history of intracranial hemorrhage. Oral anticoagulants (OACs) vs. Antiplatelets, placebo, or no treatment was evaluated on Rate of thromboembolic events, recurrent intracranial hemorrhage, and all-cause mortality. Resuming oral anticoagulants in patients with atrial fibrillation and prior intracranial hemorrhage appears to reduce mortality and thromboembolic events without significantly increasing recurrent hemorrhage risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: